DelveInsight Reports Over 80 Molecular Glue Drug Candidates in Clinical Pipeline, Highlighting Market Boom

July 26, 2026

GlobeNewswire USA

Overview

DelveInsight’s comprehensive report reveals over 80 molecular glue drug candidates in clinical development, signifying rapid expansion in this novel therapeutic modality. Key advancements include Nested Therapeutics’ early Phase I results for brain-penetrant pan-RAF/MEK molecular glue NST-628 and Amphista Therapeutics’ new preclinical data for SMARCA2 and TEAD targeting degraders. This surge in pipeline activity underscores the growing potential of molecular glues to address previously undruggable targets across various disease areas, particularly in oncology.

In Depth

Report Overview

This article provides an overview of a market research report on the clinical trial landscape of Molecular Glues, published by DelveInsight.

Key Findings

The report highlights a robust pipeline of over 80 molecular glue drug candidates currently in clinical development, signaling a significant surge in interest and investment within this innovative therapeutic area. Notable progress includes Nested Therapeutics’ announcement of initial Phase I clinical trial results for NST-628, a brain-penetrant pan-RAF/MEK molecular glue. Amphista Therapeutics has also released new preclinical data for molecular glue degraders targeting SMARCA2 and TEAD. Further, Neomorph Inc. and SEED Therapeutics presented pipeline advancements in molecular glue degraders at AACR 2026, while Degron Therapeutics initiated a Phase I trial for DEG6498, and Gluetacs Therapeutics completed patient enrollment for its GT919 Phase II study.

These developments collectively indicate that molecular glues are rapidly maturing from a nascent technology into a significant force in drug discovery, offering potential solutions for previously ‘undruggable’ targets. The diversity of targets and companies involved suggests a broad applicability, particularly in oncology and other challenging disease areas.

About the Publishing Company

DelveInsight is a life sciences market research and consulting firm, providing in-depth market analysis and pipeline intelligence across pharmaceuticals, medical devices, and biotechnology. Their reports aid pharmaceutical companies and investors in strategic decision-making by offering comprehensive insights into market dynamics and emerging therapeutic landscapes.

Source: https://www.globenewswire.com/news-release/2026/07/23/3332462/0/en/Molecular-Glues-Clinical-Trial-Landscape-80-Emerging-Competitors-Pipeline-Dynamics-and-Future-Opportunities-DelveInsight.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.